Inhaled And Intranasal Products Contract Service Providers Market Size, Share | Report 2022-2030
Report Overview
The global inhaled and intranasal products contract service providers market is anticipated to reflect a substantial growth rate across the forecast period. Respiratory disorders are becoming more common at an alarming rate. In fact, as per a Global Burden of Disease study, around 3 million global fatalities are reported annually due to chronic obstructive pulmonary disorders (COPD). This is one of the factors anticipated to drive the growth of the inhaled and intranasal products contract service providers market.
Drug delivery products such as nebulizers are in high demand owing to the significant usage of nebulizers in hospitals and home care settings. The increasing launch of the latest technology-based nebulizers such as jet nebulizers is one of the major factors propelling the demand for inhaled and intranasal products contract service providers market. Special incorporative features such as portable use in terms of systematic drug delivery, reducing inhalation time, and improving the delivered dosing have further supported the growth of inhaled and intranasal products contract service providers market.
The COVID-19 restrictions had disrupted the medical device supply chain and completely halted research-based activities, which has directly impacted the production of novel medical devices. However, with the ease of restrictions in the second half of 2020 and substantial economic recovery, the inhaled and intranasal products contract service providers market is projected to witness lucrative growth in the forecast period.
In terms of services, the contract manufacturing segment is projected to maintain its dominant position in the forecast period. The increasing focus of manufacturers on reducing the cost of medical devices and increased complexity in manufacturing has substantially created a demand for outsourcing services thereby contributing to the inhaled and intranasal products contract service providers market growth.
The global inhaled and intranasal products contract service providers market in North America is anticipated to hold the highest market share in the forecast period owing to factors such as ease of regulatory compliance, the presence of a large number of contract manufacturers, and increasing respiratory diseases such as COPD. For instance, according to research by the centers for disease control and prevention (CDC), COPD affected over 15 million people in the U.S. in 2021.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Inhaled And Intranasal Products Contract Service Providers Market
5.1. COVID-19 Landscape: Inhaled And Intranasal Products Contract Service Providers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Inhaled And Intranasal Products Contract Service Providers Market, By Drug Delivery Product
8.1. Inhaled And Intranasal Products Contract Service Providers Market, by Drug Delivery Product, 2022-2030
8.1.1. Metered- dose inhalers (MDIs)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Dry Powder Inhalers
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Nebulizers
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Inhaled And Intranasal Products Contract Service Providers Market, By Services
9.1. Inhaled And Intranasal Products Contract Service Providers Market, by Services, 2022-2030
9.1.1. Quality Assurance
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Regulatory Affair Services
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Product Design and Development
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Product Testing and Sterilization
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Product Implementation
9.1.5.1. Market Revenue and Forecast (2017-2030)
9.1.6. Product Upgrade
9.1.6.1. Market Revenue and Forecast (2017-2030)
9.1.7. Product Mainentance
9.1.7.1. Market Revenue and Forecast (2017-2030)
9.1.8. Contract Manufacturing
9.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Inhaled And Intranasal Products Contract Service Providers Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.1.2. Market Revenue and Forecast, by Services (2017-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.1.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.1.4.2. Market Revenue and Forecast, by Services (2017-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.2.2. Market Revenue and Forecast, by Services (2017-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.2.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.2.4.2. Market Revenue and Forecast, by Services (2017-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.2.5.2. Market Revenue and Forecast, by Services (2017-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.2.6.2. Market Revenue and Forecast, by Services (2017-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.3.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.3.4.2. Market Revenue and Forecast, by Services (2017-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.3.5.2. Market Revenue and Forecast, by Services (2017-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.3.6.2. Market Revenue and Forecast, by Services (2017-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.4.2. Market Revenue and Forecast, by Services (2017-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.4.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.4.4.2. Market Revenue and Forecast, by Services (2017-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.4.5.2. Market Revenue and Forecast, by Services (2017-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.4.6.2. Market Revenue and Forecast, by Services (2017-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.5.2. Market Revenue and Forecast, by Services (2017-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.5.3.2. Market Revenue and Forecast, by Services (2017-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Delivery Product (2017-2030)
10.5.4.2. Market Revenue and Forecast, by Services (2017-2030)
Chapter 11. Company Profiles
11.1. Lonza
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Catalent Inc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Kindeva Drug Delivery
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Recipharm
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Quotient Services
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Hovione
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Colep
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Beximo Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. DPT Laboratories
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Orion
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers